Jason M. Broderick

Sexual activity, sexual desire, and physical function were improved by testosterone replacement therapy in men with hypogonadism post-prostatectomy.

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan has elicited antitumor activity across subtypes of extrapulmonary neuroendocrine carcinomas.

INBRX-106 may act as a costimulatory agent and enhance pembrolizumab outcomes in head and neck squamous cell carcinoma.

The FDA has approvesd zenocutuzumab-zbco for previously treated NRG1 fusion–positive cholangiocarcinoma cholangiocarcinoma.

The FDA previously granted RZ-001 both orphan drug designation and fast track designation for hepatocellular carcinoma.

The phase 1/2 data led to the phase 3 RASolute 302 trial which supported the FDA's allowance of early access to daraxonrasib in PDAC.

Intraperitoneal rintatolimod may boost outcomes with immunotherapies such as pembrolizumab in ovarian cancer.

The FDA has authorized expanded access to the RAS inhibitor daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.

Darlifarnib may enable the rechallenging of patients with cabozantinib in a combination context for patients with clear cell renal cell carcinoma.

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

A new integrated treatment regimen significantly enhances PFS vs standard chemotherapy in metastatic pancreatic cancer.

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

The MajesTEC-3 trial showed that teclistamab combined with subcutaneous daratumumab improved overall survival vs standard daratumumab-based regimens in relapsed/refractory multiple myeloma.

Pirtobrutinib shows superior overall response rates and promising progression-free survival compared to ibrutinib in treating chronic lymphocytic leukemia.

Gintemetostat shows promising efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

The FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell lung cancer.

The FDA has approved sevabertinib for HER2-mutant nonsquamous non–small cell lung cancer.

At the 43rd Annual CFS meeting, John Allan, MD, highlighted ongoing efforts to advance the treatment paradigm for chronic lymphocytic leukemia.

The FDA has approved daratumumab and hyaluronidase for the treatment of patients with high-risk smoldering multiple myeloma.

Jonathan Strosberg, MD, details findings with 212Pb-DOTAMTATE in patients with gastroenteropancreatic neuroendocrine tumors from the ALPHAMEDIX-02 trial.

A groundbreaking study reveals 212Pb-DOTAMTATE's promising efficacy and safety in treating advanced gastroenteropancreatic neuroendocrine tumors.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

The ALPHAMEDIX-02 trial showed promising results for 212Pb-DOTAMTATE in previously treated gastroenteropancreatic neuroendocrine tumors.

The SKYSCRAPER-03 trial showed that consolidation tiragolumab plus atezolizumab does not improve progression-free survival in advanced lung cancer compared to durvalumab.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

A new drug application for Dasynoc was not approved for patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Replimune navigates FDA challenges for RP1, an innovative melanoma treatment, while emphasizing the urgent need for effective therapies in advanced cases.